# Efficacy and safety of later-line targeted therapies in advanced non-small cell lung cancer with EGFR exon 20 insertion mutations: a systematic review

## TL;DR

This review evaluates new targeted therapies for advanced lung cancer with EGFR exon 20 mutations, finding them more effective and safer than traditional treatments.

## Contribution

The study provides the first systematic review of later-line targeted therapies for EGFR exon 20 insertion mutations in NSCLC.

## Key findings

- Targeted therapies showed a 41.8% objective response rate and 85.6% disease control rate in ex20ins-positive NSCLC.
- Median progression-free survival was 8.02 months, and median overall survival was 20.8 months.
- Common side effects included diarrhea, rash, and paronychia, with most being manageable.

## Abstract

Platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) are currently regarded as the standard treatment modalities for advanced non-small cell lung cancer (NSCLC) characterized by EGFR exon 20 insertion (ex20ins) mutations; however, their efficacy is suboptimal. Recent developments in targeted therapies, including agents such as amivantamab, mobocertinib, and sunvozertinib, have shown promise in patients with pretreated ex20ins-positive NSCLC. However, a comprehensive systematic review assessing the efficacy and safety of these later-line Targeted therapies has not yet been conducted.

A systematic search for studies pertaining to later-line treatment options for patients with ex20ins mutations was conducted using PubMed, Embase, and the Cochrane Library, with a cutoff date of 31 March 2025, without language restrictions. The primary endpoints of this review were the objective response rate (ORR) and disease control rate (DCR), whereas the secondary endpoints included progression-free survival (PFS), overall survival (OS), and the incidence of treatment-related adverse events (TRAEs).

Eleven studies were included in this analysis, with efficacy data encompassing 788 participants and safety data involving 861 participants. The pooled ORR for novel targeted therapies in the later-line setting was 41.8% (95% CI: 35.3%–48.3%), and the DCR was 85.6% (95% CI: 80.1%–91.1%). The pooled median PFS from eight studies was 8.020 months (95% CI: 7.203–8.930), and the pooled median OS from four studies was 20.804 months (95% CI: 16.713–25.896). Subgroup analysis indicated that there were differences in the pooled ORR for patients with near-loop insertions and far-loop insertions (44.4% vs. 34.5%) or patients with or without baseline brain metastasis (36.4% vs. 47.5%), although neither difference was significant (both P > 0.05). The most common all-grade TRAEs were diarrhea (66.8%),rash (66.7%), paronychia (42.0%). Among grade ≥3 events, diarrhea was the most frequently reported (10.1%), followed by rash (8.2%) and anemia (2.7%).

Novel targeted therapies demonstrate superior efficacy and acceptable safety compared to conventional later-line treatments in advanced NSCLC with EGFR ex20ins mutations, though further validation through randomized controlled trials is warranted.

https://www.crd.york.ac.uk/PROSPERO/view/CRD420251056825. No amendments were made to the registered protocol after commencement of the review. The full review protocol can be accessed on the PROSPERO database (Registration number: CRD420251056825).